Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.
Antibody-drug conjugate
DOI:
10.1200/jco.2018.36.15_suppl.e24206
Publication Date:
2018-09-05T14:54:16Z
AUTHORS (16)
ABSTRACT
e24206 Background: DS-1062a is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of humanized anti-TROP2 monoclonal antibody, enzymatically cleavable peptide-linker, and novel topoisomerase I inhibitor DXd which derivative Exatecan (DX-8951). TROP2 36-kDa single-pass transmembrane overexpressed in various epithelial tumors including non-small lung cancer (NSCLC) with relatively low restricted expression normal tissues, associated aggressive tumor behavior. Therefore, could be an attractive target for therapy. Methods: In vitro growth inhibitory vivo anti-tumor activities were evaluated using TROP2-positive negative lines xenograft mice models. Pharmacokinetic safety profiles also assessed cynomolgus monkeys. Results: showed activity to cells (CFPAC-1, BxPC-3 (pancreas adenocarcinoma)) IC50 values 706 ng/mL 74.6 ng/mL, respectively, but not TROP2-negative (Calu-6 (anaplastic carcinoma)) value > 20000 ng/mL. induced dose-dependent inhibition regression at more than 1 mg/kg single dosing the CFPAC-1 model contrast isotype control IgG-ADC antibody no efficacy. exhibited stronger higher concentrations TROP2-high compared TROP2-low or several addition, favorable pharmacokinetic acceptable Conclusions: Based on these preclinical results, provide valuable therapy potential benefit cancers clinical setting. A first-in-human phase study patients advanced solid progress (NCT03401385).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (11)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....